their-world

Exclusive: Pfizer weighs sale or spin-off of consumer health unit – sources

By Lauren Hirsch, Olivia Oran and Carl O'Donnell (Reuters) – U.S. drugmaker Pfizer Inc is evaluating a potential sale or spin-off of its consumer health division that could value the unit at as much as $14 billion, people familiar with the matter said on Wednesday. A Pfizer exit from the consumer health business, which includes lip balm Chapstick and painkiller Advil, would be one of its biggest corporate moves since abandoning a $160 billion deal to buy Irish drugmaker Allergan Inc earlier this year…

Read the original:
Exclusive: Pfizer weighs sale or spin-off of consumer health unit – sources

their-world

U.S. appeals court declines to reconsider Bank of America ruling

A U.S. appeals court refused on Monday to reconsider its decision to overturn a $1.27 billion penalty against Bank of America Corp and a jury verdict finding it liable for mortgage fraud leading up to the 2008 financial crisis. The 2nd U.S. Circuit Court of Appeals in New York rejected a petition by Manhattan U.S. Attorney Preet Bharara's office to have a three-judge panel rehear the case and give the government at least an opportunity to seek a new trial. Bharara's office had argued…

See original here: 
U.S. appeals court declines to reconsider Bank of America ruling

their-world

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Medivation shares were up 20 percent at $80.43 in afternoon trading, just shy of the offer price of $81.50 per share. Shares of Pfizer, the largest U.S. drugmaker, were down 0.5 percent at $34.82. The offer is a 55-percent premium to Sanofi SA's initial offer to buy Medivation for $52.50 in April that pushed the San Francisco-based company to put itself up for sale.

Original post:
Pfizer boosts cancer drug roster with $14 billion Medivation deal